1. Phase III randomised trial of pegylated liposomal doxorubicin plus carboplatin versus carboplatin in platinum sensitive patients with recurrent epithelial ovarian cancer or peritoneal carcinoma after failure of initial platinum-based chemotherapy: Southwest Oncology group Protocol SO200;Alberts;Journal of Clinical Oncology,2007
2. Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials;Blackledge;British Journal of Cancer,1989
3. Gynaecologic Cancer Intergroup through the gynaecological oncology group: GOGO182-ICON5: 5-arm phse III randomised trial of paclitaxel (P) and carboplatin (C) versus combinations with gemcitabine (G), liposomal doxorubicin (D) or topotecan (T) in patients with advanced stage epithelial ovarian or primary peritoneal cancer;Bookman;Journal of Clinical Oncology,2006
4. Cancer Research UK UK Ovarian Cancer Incidence Statistics www.cancerresearchuk.org/cancerstats/type/ovary
5. Bevacuzimab in patients with advanced platinum-resistant ovarian cancer;Cannistra;Journal of Clinical Oncology,2006